Don’t miss Friday’s keynote at the Global CMT Research Convention (September 24 to 26, 2026, Cambridge, MA), featuring Dr. Anna Greka, founder of the Ladders to Cures (L2C) Scientific Accelerator at the Broad Institute of MIT and Harvard.
Rare genetic diseases are collectively common, affecting roughly 400 million people worldwide, yet fewer than 500 of the nearly 8,000 identified conditions have any treatment. L2C brings together scientists, patient advocates, AI experts, and biopharma veterans to close that gap by finding “nodal” biological pathways that cut across many diseases at once, rather than chasing one disease at a time.
For CMT researchers and industry, that framework has a direct upside: a nodal approach means the next CMT breakthrough could come from a discovery made in an entirely different disease, and vice versa.
The keynote will pose a question every researcher, funder, and industry partner in the room has a stake in: how do we support the rare disease community?
Dr. Anna Greka is a core institute member of the Broad Institute of MIT and Harvard and a physician at Mass General Brigham. Her lab discovered that many seemingly unrelated genetic diseases, in the kidney, eye, and brain, converge on shared nodal pathways, opening the door to treating multiple genetic diseases with a single drug. Read more about her work here.
This work has already reached a national audience. In March 2026, Dr. Greka joined n-Lorem Foundation CEO Dr. Stan Crooke for a conversation as part of CNBC Cures on how gene editing and ASO therapies are enabling targeted treatments for conditions once considered untreatable. L2C is a partner and collaborator on the CNBC Cures initiative.
For researchers, drug developers, and investors in the CMT space, this keynote is a preview of where the field is headed, not a look back.
